MCID: DBT004
MIFTS: 52

Diabetic Polyneuropathy malady

Categories: Endocrine diseases, Neuronal diseases

Aliases & Classifications for Diabetic Polyneuropathy

About this section

Aliases & Descriptions for Diabetic Polyneuropathy:

Name: Diabetic Polyneuropathy 11 50 13
Diabetes Mellitus with Polyneuropathy 11
 
Polyneuropathy in Diabetes 11
Diabetic Polyneuropathies 68

Classifications:



Summaries for Diabetic Polyneuropathy

About this section
MalaCards based summary: Diabetic Polyneuropathy, also known as diabetes mellitus with polyneuropathy, is related to polyneuropathy and congenital toxoplasmosis. An important gene associated with Diabetic Polyneuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways are Detoxification of Reactive Oxygen Species and Oxidative Stress. Affiliated tissues include testes, spinal cord and skin, and related mouse phenotypes are neoplasm and digestive/alimentary.

Related Diseases for Diabetic Polyneuropathy

About this section

Diseases related to Diabetic Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 52)
idRelated DiseaseScoreTop Affiliating Genes
1polyneuropathy10.8
2congenital toxoplasmosis10.2AKR1B1, VEGFA
3acute gonococcal cystitis10.1TP53, VEGFA
4low compliance bladder10.1SOD2, TNF
5neuropathy10.1
6coronary stenosis10.1TP53, VEGFA
7degenerative disc disease10.1TNF, VEGFA
8pyloric antrum cancer10.1TP53, VEGFA
9adult brainstem gliosarcoma10.1NGF, TP53
10bipolar i disorder10.1TNF, VEGFA
11lung occult small cell carcinoma10.1NGF, TP53
12blood group incompatibility10.1NGF, TP53
13white piedra10.1AKR1B1, POLG, VEGFA
14acute mountain sickness10.1TNF, TP53
15vogt-koyanagi-harada disease10.0TNF, VEGFA
16gallbladder pleomorphic giant cell adenocarcinoma10.0NGF, TP53
17adult epithelioid sarcoma10.0NGF, TP53
18breast fibroadenoma10.0NTF3, VEGFA
19adult neuronal ceroid lipofuscinosis10.0NGF, VEGFA
20benign idiopathic neonatal seizures10.0TNF, VEGFA
21tinea capitis10.0NGF, TNF
22conjunctival concretion9.9SOD2, TNF, TP53
23necrobiosis lipoidica9.9SOD2, TNF, TP53
24ulcerative proctitis9.9TNF, VEGFA
25spastic paraplegia 19.9TNF, TP53, VEGFA
26gastroduodenal crohn's disease9.9NGF, TNF
27placenta praevia9.9TNF, TP53, VEGFA
28substance-induced psychosis9.9NGF, TNF, VEGFA
29diabetic neuropathy9.9
30autonomic neuropathy9.9
31ovarian brenner tumor9.9TNF, TP53, VEGFA
32rumination disorder9.9AKR1B1, NGF, NTF3
33fissured tongue9.9AKR1B1, NGF, NTF3
34endotheliitis9.8
35chronic inflammatory demyelinating polyneuropathy9.7
36ischemia9.7
37hyperglycemia9.7
38demyelinating polyneuropathy9.7
39chronic pain9.7
40cutis laxa, autosomal recessive, type ib9.7TNF, TP53, VEGFA
41neuroblastoma9.5
42obesity9.5
43diabetic foot ulcers9.5
44mononeuropathy9.5
45tarsal tunnel syndrome9.5
46vestibular disease9.5
47retinitis9.5
48pancreatitis9.5
49autonomic dysfunction9.5
50postherpetic neuralgia9.5

Comorbidity relations with Diabetic Polyneuropathy via Phenotypic Disease Network (PDN):

(show all 33)
Deficiency AnemiaDermatomycosis
Acute CystitisAcute Kidney Failure
Benign Essential HypertensionBronchitis
Chronic Kidney FailureChronic Myocardial Ischemia
Decubitus UlcerDiabetic Cataract
EsophagitisFamilial Atrial Fibrillation
Generalized AtherosclerosisHeart Disease
Hypertension, EssentialIntermediate Coronary Syndrome
Ischemic Heart DiseaseKidney Disease
Microvascular Complications of Diabetes 1Microvascular Complications of Diabetes 7
Mitral Valve DiseaseNeurogenic Arthropathy
Neurogenic BladderPartial Third-Nerve Palsy
Peripheral Vascular DiseaseRespiratory Failure
Transient Cerebral IschemiaHypoglycemia
Hypoglycemic ComaHypothyroidism
Mononeuritis MultiplexMononeuropathy of the Median Nerve, Mild
Tabes Dorsalis

Graphical network of the top 20 diseases related to Diabetic Polyneuropathy:



Diseases related to diabetic polyneuropathy

Symptoms & Phenotypes for Diabetic Polyneuropathy

About this section

MGI Mouse Phenotypes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

41 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.4POLG, SOD2, TNF, TP53, VEGFA
2MP:00053818.0CYBA, POLG, TNF, TP53, VEGFA
3MP:00053887.9CYBA, NTF3, TNF, TP53, VEGFA
4MP:00053907.9AKR1B1, POLG, SOD3, TNF, TP53, VEGFA
5MP:00053897.9NTF3, POLG, SOD2, TNF, TP53, VEGFA
6MP:00053757.8CYBA, POLG, SOD2, TNF, TP53
7MP:00053877.4CYBA, POLG, SOD2, SOD3, TNF, TP53
8MP:00107717.4NGF, POLG, SOD2, TNF, TP53, VEGFA
9MP:00030127.3NGF, POLG, SOD3, TNF, TP53, VEGFA
10MP:00053697.0NGF, NTF3, POLG, SOD2, TNF, TP53
11MP:00053916.9AKR1B1, CYBA, NGF, NTF3, SOD2, TNF
12MP:00053866.9AKR1B1, CYBA, NGF, NTF3, SOD2, TNF
13MP:00053856.6CYBA, NGF, NTF3, POLG, SOD2, TNF
14MP:00107686.4AKR1B1, NGF, NTF3, POLG, SOD2, SOD3
15MP:00053786.3AKR1B1, CYBA, NGF, NTF3, POLG, SOD2
16MP:00036316.1CYBA, NGF, NTF3, POLG, SOD2, TNF
17MP:00053766.0AKR1B1, CYBA, NGF, NTF3, POLG, SOD2

Drugs & Therapeutics for Diabetic Polyneuropathy

About this section

Drugs for Diabetic Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 123)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Pregabalinapproved, illicit, investigationalPhase 4, Phase 2, Phase 1361148553-50-85486971
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3-Isobutyl gaba
3-isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
CID5486971
 
D02716
DB00230
FT-0080911
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
2
CilostazolapprovedPhase 410673963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
3
NorepinephrineapprovedPhase 4, Phase 269951-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
LT03330026
 
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Nor-adrenaline
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
4
Lidocaineapproved, vet_approvedPhase 4, Phase 21317137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
5
AcetylcholineapprovedPhase 4, Early Phase 180551-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
6
DopamineapprovedPhase 4, Phase 2383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
7
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
8Protective AgentsPhase 4, Phase 2, Phase 37443
9AntioxidantsPhase 4, Phase 2, Phase 33050
10VitaminsPhase 4, Phase 3, Phase 25282
11Vitamin B ComplexPhase 4, Phase 3, Phase 24337
12Thioctic AcidPhase 4, Phase 2, Phase 3118
13Trace ElementsPhase 4, Phase 3, Phase 26001
14Anti-Anxiety AgentsPhase 4, Phase 3, Phase 2, Phase 11885
15Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 123689
16AnticonvulsantsPhase 4, Phase 3, Phase 2, Phase 12695
17Tranquilizing AgentsPhase 4, Phase 3, Phase 2, Phase 14265
18Psychotropic DrugsPhase 4, Phase 3, Phase 2, Phase 16430
19Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 113403
20AnalgesicsPhase 4, Phase 3, Phase 2, Phase 111733
21MicronutrientsPhase 4, Phase 3, Phase 26001
22calcium channel blockersPhase 4, Phase 3, Phase 2, Phase 11985
23Calcium, DietaryPhase 4, Phase 3, Phase 2, Phase 15713
24Serotonin and Noradrenaline Reuptake InhibitorsPhase 4, Phase 2457
25
SerotoninPhase 4, Phase 2362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
26Neurotransmitter Uptake InhibitorsPhase 4, Phase 23521
27Diuretics, Potassium SparingPhase 4, Phase 21917
28Analgesics, OpioidPhase 4, Phase 3, Phase 23238
29NarcoticsPhase 4, Phase 3, Phase 23646
30Sodium Channel BlockersPhase 4, Phase 21593
31Duloxetine HydrochloridePhase 4, Phase 2270
32Anesthetics, LocalPhase 4, Phase 23492
33Anti-Arrhythmia AgentsPhase 4, Phase 23093
34AnestheticsPhase 4, Phase 29596
35onabotulinumtoxinAPhase 4, Early Phase 1652
36Phosphodiesterase InhibitorsPhase 41289
37Platelet Aggregation InhibitorsPhase 42516
38Respiratory System AgentsPhase 44997
39Dopamine AgentsPhase 4, Phase 23836
40Phosphodiesterase 3 InhibitorsPhase 4133
41Neuroprotective AgentsPhase 4, Phase 21716
42Anti-Asthmatic AgentsPhase 43488
43Autonomic AgentsPhase 4, Phase 310150
44Bronchodilator AgentsPhase 42965
45Fibrinolytic AgentsPhase 42388
46abobotulinumtoxinAPhase 4, Early Phase 1652
47Vasodilator AgentsPhase 43543
48Antidepressive AgentsPhase 4, Phase 22736
49Neuromuscular AgentsPhase 4, Early Phase 11180
50incobotulinumtoxinAPhase 4, Early Phase 1662

Interventional clinical trials:

(show top 50)    (show all 98)
idNameStatusNCT IDPhase
1Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic NeuropathyUnknown statusNCT01770964Phase 4
2Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the PhilippinesCompletedNCT01076478Phase 4
3Botulinum Toxin in Peripheral Neuropathic PainCompletedNCT01251211Phase 4
4Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive DisorderCompletedNCT00844194Phase 4
5Alpha Lipoic Acid for Treatment of Diabetic NeuropathyCompletedNCT02439879Phase 4
6Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic NeuropathyCompletedNCT00903851Phase 4
7Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label StudyCompletedNCT00614341Phase 4
8Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or PregabalinWithdrawnNCT01116531Phase 4
9Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)Unknown statusNCT01868191Phase 3
10Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric PolyneuropathyUnknown statusNCT01224353Phase 2, Phase 3
11Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)CompletedNCT00977483Phase 3
12Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic NeuropathyCompletedNCT00993070Phase 2, Phase 3
13Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)CompletedNCT00328601Phase 3
14Neuropathic Pain ManagementCompletedNCT01263132Phase 3
15Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)CompletedNCT00483730Phase 3
16TempTouch IR Thermometry & Diabetic Patient Self-CareCompletedNCT00289497Phase 2, Phase 3
17A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral NeuropathyCompletedNCT00455520Phase 3
18Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor PolyneuropathyCompletedNCT00927914Phase 2, Phase 3
19Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor PolyneuropathyCompletedNCT00101426Phase 3
20Safety and Efficacy Study of Fx-1006A in Patients With Familial AmyloidosisCompletedNCT00409175Phase 2, Phase 3
21An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid PolyneuropathyCompletedNCT00791492Phase 2, Phase 3
22A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral NeuropathyCompletedNCT01041859Phase 3
23The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M TransthyretinCompletedNCT01435655Phase 3
24Muscarinic Receptor Antagonists as a Therapy for Diabetic NeuropathyRecruitingNCT03050827Phase 3
25Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid PolyneuropathyActive, not recruitingNCT01737398Phase 3
26Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)Enrolling by invitationNCT02175004Phase 3
27The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)Enrolling by invitationNCT02510261Phase 3
28A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)TerminatedNCT01063868Phase 3
29Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral NeuropathyUnknown statusNCT01175928Phase 1, Phase 2
30Lidorestat (IDD 676) for the Treatment of Diabetic NeuropathyUnknown statusNCT00043797Phase 2
31The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled StudyCompletedNCT01622777Phase 2
32Painful Diabetic Polyneuropathy Trial With a New Centrally Acting AnalgesicCompletedNCT00878293Phase 2
33Safety and Efficacy of MCC-257 in the Treatment of Diabetic PolyneuropathyCompletedNCT00307749Phase 2
34Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and GastroparesisCompletedNCT01607684Phase 2
35Statins for Oxidative Stress and Mitochondrial Function in Diabetic PolyneuropathyCompletedNCT02129231Phase 2
36A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic PoCompletedNCT00944697Phase 2
37Safety and Efficacy of GRT6005 in Pain Due to Diabetic PolyneuropathyCompletedNCT01347671Phase 2
38A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic PolyneuropathyCompletedNCT01201317Phase 2
39Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral NeuropathyCompletedNCT01469559Phase 2
40Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT01079325Phase 2
41Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00406458Phase 2
42Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509CompletedNCT00665145Phase 2
43Effect of C-Peptide on Diabetic Peripheral NeuropathyCompletedNCT00278980Phase 2
44Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00476931Phase 2
45Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).CompletedNCT00501202Phase 2
46Safety and Efficacy Study in Subjects With Diabetic Neuropathic PainCompletedNCT00507936Phase 2
47Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral NeuropathyCompletedNCT00229437Phase 2
48A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic PainCompletedNCT01345045Phase 2
49Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral NeuropathyCompletedNCT00760955Phase 2
50A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral PolyneuropathyCompletedNCT00231673Phase 2

Search NIH Clinical Center for Diabetic Polyneuropathy

Genetic Tests for Diabetic Polyneuropathy

About this section

Anatomical Context for Diabetic Polyneuropathy

About this section

MalaCards organs/tissues related to Diabetic Polyneuropathy:

36
Testes, Spinal cord, Skin, Pancreas, Bone, Endothelial, Skeletal muscle

Publications for Diabetic Polyneuropathy

About this section

Articles related to Diabetic Polyneuropathy:

(show top 50)    (show all 338)
idTitleAuthorsYear
1
Oxytocin provides protection against diabetic polyneuropathy in rats. (27881053)
2017
2
The Facilitative Effect of Transcranial Direct Current Stimulation on Visuospatial Working Memory in Patients with Diabetic Polyneuropathy: A Pre-post Sham-Controlled Study. (27733822)
2016
3
Is Stem Cell Transplantation Ready for Prime Time in Diabetic Polyneuropathy? (27485630)
2016
4
Comparative analysis of the effects combined physical procedures and alpha-lipoic acid on the electroneurographic parameters of patients with distal sensorimotor diabetic polyneuropathy. (27065527)
2016
5
Sonographic features of peripheral nerves at multiple sites in patients with diabetic polyneuropathy. (26782023)
2016
6
Cardiovascular Autonomic Dysfunction Predicts Diabetic Foot Ulcers in Patients With Type 2 Diabetes Without Diabetic Polyneuropathy. (27015188)
2016
7
Physical activity and albuminuria were associated with painful diabetic polyneuropathy in type 2 diabetes in an ethnic Chinese population. (27592367)
2016
8
Abnormalities of retinal ganglion cell complex at optical coherence tomography in patients with type 2 diabetes: a sign of diabetic polyneuropathy, not retinopathy. (26809902)
2016
9
Fiber loss in diabetic polyneuropathy. (27253717)
2016
10
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study. (26881251)
2016
11
Sensitive detection of hemodynamic failure during orthostatic stress in patients with diabetic polyneuropathy using a mini laser Doppler blood flowmeter. (27939526)
2016
12
Might genetics play a role in understanding and treating diabetic polyneuropathy? (28032668)
2016
13
Overcoming barriers to diabetic polyneuropathy management in primary care. (27939169)
2016
14
Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial. (27417167)
2016
15
A standardized clinical evaluation of phenotypic diversity in diabetic polyneuropathy. (27322439)
2016
16
Independent Risk Factors for Positive and Negative Symptoms in Patients with Diabetic Polyneuropathy. (27337438)
2016
17
High Plasma Pentraxin 3 Levels in Diabetic Polyneuropathy Patients with Nociceptive Pain. (27212074)
2016
18
Molecular underpinnings of diabetic polyneuropathy. (27451278)
2016
19
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. (28058263)
2016
20
Spinal cord stimulation in experimental chronic painful diabetic polyneuropathy: Delayed effect of High-frequency stimulation. (27891705)
2016
21
Predictors of improvement and progression of diabetic polyneuropathy following treatment with I+-lipoic acid for 4years in the NATHAN 1 trial. (26651260)
2016
22
Transplantation of cultured dental pulp stem cells into the skeletal muscles ameliorated diabetic polyneuropathy: therapeutic plausibility of freshly isolated and cryopreserved dental pulp stem cells. (26345292)
2015
23
Response to research letter in relation to paper by Bongaerts et al., a clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies (a single question screening test for the detection of diabetic peripheral neuropathy). (25498299)
2015
24
Nerve conduction studies after decompression in painful diabetic polyneuropathy. (26035677)
2015
25
Association of Peripheral Autonomic Neuropathy and Sympathetic Skin Response in the Patients with Diabetic Polyneuropathy: A Pilot Study in Thailand. (27004308)
2015
26
The effect of lower extremity nerve decompression on health-related quality of life and perception of pain in patients with painful diabetic polyneuropathy: a prospective randomized trial. (25712758)
2015
27
Transplantation of dental pulp stem cells suppressed inflammation in sciatic nerves by promoting macrophage polarization towards anti-inflammation phenotypes and ameliorated diabetic polyneuropathy. (27181261)
2015
28
Proposal of a new method for the use of the Rydel-Seiffer tuning fork in the screening of diabetic polyneuropathy. A pilot study. (25773377)
2015
29
Pathways in the diagnosis and management of diabetic polyneuropathy. (25899758)
2015
30
DIAGNOSTICS ALGORITHM OF DIABETIC POLYNEUROPATHY IN PREDICTION OF CLINICAL COURSE. (26887136)
2015
31
Association study of C936T polymorphism of the VEGF gene and the C242T polymorphism of the p22phox gene with diabetes mellitus type 2 and distal diabetic polyneuropathy. (26130419)
2015
32
Research letter in relation to paper by Bongaerts et al., a clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies. (25498301)
2015
33
A clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies. (25457462)
2015
34
Angioblast Derived from ES Cells Construct Blood Vessels and Ameliorate Diabetic Polyneuropathy in Mice. (25977928)
2015
35
An 'Importance' Map of Signs and Symptoms to Classify Diabetic Polyneuropathy: An Exploratory Data Analysis. (26075711)
2015
36
Reduced skeletal muscle quantity and quality in patients with diabetic polyneuropathy assessed by magnetic resonance imaging. (26202052)
2015
37
Upregulation of axonal HCN current by methylglyoxal: Potential association with diabetic polyneuropathy. (25823697)
2015
38
The ultrasonographic evaluation of hemodynamic changes in patients with diabetic polyneuropathy after tarsal tunnel decompression. (26235134)
2015
39
Diabetic polyneuropathy and the risk of developing diabetic retinopathy: a nationwide, population-based study. (25989925)
2015
40
Selecting a prospective test for early detection of diabetic polyneuropathy. (25847628)
2015
41
Nerve conduction studies in diabetics presymptomatic and symptomatic for diabetic polyneuropathy. (26049172)
2015
42
Measurement of small fibre pain threshold values for the early detection of diabetic polyneuropathy. (25970541)
2015
43
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy--authors' reply. (26067119)
2015
44
Therapeutic efficacy of bone marrow-derived mononuclear cells in diabetic polyneuropathy is impaired with aging or diabetes. (25802721)
2015
45
Tarsal tunnel syndrome masked by painful diabetic polyneuropathy. (26333036)
2015
46
Methylglyoxal modulates axonal excitability in diabetic polyneuropathy: A potential pathophysiological link? (25836600)
2015
47
NEAR-NERVE NEEDLE TECNIQUE VERSUS SURFACE ELECTRODE RECORDINGS IN ELECTRODIAGNOSIS OF DIABETIC POLYNEUROPATHY. (26657238)
2015
48
Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy. (26067117)
2015
49
From treatment to preventive actions: improving function in patients with diabetic polyneuropathy. (26452065)
2015
50
Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and A/-opioid receptor agonism. (25697471)
2015

Variations for Diabetic Polyneuropathy

About this section

Expression for genes affiliated with Diabetic Polyneuropathy

About this section
Search GEO for disease gene expression data for Diabetic Polyneuropathy.

Pathways for genes affiliated with Diabetic Polyneuropathy

About this section

Pathways related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 17)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.4CYBA, SOD2, SOD3
29.4CYBA, SOD2, SOD3
39.3NGF, TNF
49.3TP53, VEGFA
59.0NGF, NTF3, VEGFA
69.0NGF, TNF, VEGFA
7
Show member pathways
8.8NGF, NTF3, TNF
88.8TNF, TP53, VEGFA
98.8TNF, TP53, VEGFA
108.8TNF, TP53, VEGFA
11
Show member pathways
8.5NGF, NTF3, TP53
12
Show member pathways
8.5SOD2, SOD3, TNF, TP53
138.3CYBA, TNF, TP53, VEGFA
14
Show member pathways
8.2CYBA, SOD2, SOD3, TP53, VEGFA
15
Show member pathways
8.1NGF, NTF3, TP53, VEGFA
16
Show member pathways
8.1CYBA, NGF, TNF, TP53
17
Show member pathways
8.0NGF, NTF3, TNF, TP53

GO Terms for genes affiliated with Diabetic Polyneuropathy

About this section

Biological processes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 24)
idNameGO IDScoreTop Affiliating Genes
1hydrogen peroxide biosynthetic processGO:005066510.5CYBA, SOD2
2removal of superoxide radicalsGO:001943010.4SOD2, SOD3
3induction of positive chemotaxisGO:005093010.3NTF3, VEGFA
4positive chemotaxisGO:005091810.3NTF3, VEGFA
5response to hyperoxiaGO:005509310.3POLG, SOD2
6positive regulation of protein complex assemblyGO:003133410.2TNF, VEGFA
7positive regulation of receptor internalizationGO:000209210.2NTF3, VEGFA
8positive regulation of phagocytosisGO:005076610.2CYBA, TNF
9cellular response to oxidative stressGO:003459910.1CYBA, SOD2, SOD3
10superoxide anion generationGO:004255410.1CYBA, SOD2
11extrinsic apoptotic signaling pathway via death domain receptorsGO:000862510.1NGF, TNF
12negative regulation of fibroblast proliferationGO:004814710.0SOD2, TP53
13cellular response to gamma radiationGO:007148010.0CYBA, TP53
14positive regulation of cell migrationGO:003033510.0NTF3, SOD2, VEGFA
15regulation of neuron differentiationGO:00456649.9NGF, NTF3
16positive regulation of smooth muscle cell proliferationGO:00486619.9AKR1B1, CYBA, TNF
17negative regulation of neuron apoptotic processGO:00435249.7NGF, NTF3, SOD2
18positive regulation of peptidyl-serine phosphorylationGO:00331389.7NTF3, TNF, VEGFA
19response to gamma radiationGO:00103329.5POLG, SOD2, TP53
20response to hypoxiaGO:00016669.4CYBA, SOD2, SOD3, VEGFA
21positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.4NTF3, TP53, VEGFA
22superoxide metabolic processGO:00068019.4CYBA, SOD2, SOD3
23positive regulation of gene expressionGO:00106288.8NGF, TNF, TP53, VEGFA
24negative regulation of apoptotic processGO:00430668.8AKR1B1, NGF, SOD2, TP53, VEGFA

Molecular functions related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1chemoattractant activityGO:004205610.3NTF3, VEGFA
2superoxide dismutase activityGO:00047849.8SOD2, SOD3
3growth factor activityGO:00080839.6NGF, NTF3, VEGFA
4oxidoreductase activityGO:00164919.6AKR1B1, CYBA, SOD2, SOD3
5protease bindingGO:00020208.8POLG, TNF, TP53

Sources for Diabetic Polyneuropathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet